Experimental Pathology Laboratories, Inc. (EPL) Acquires Aclairo Pharmaceutical Development Group, Inc.
STERLING, Va., Jan. 13, 2016 /PRNewswire/ -- Experimental Pathology Laboratories, Inc. (EPL) announced today that it has acquired Aclairo Pharmaceutical Development Group, Inc. (Aclairo).
Dr. Jerry Hardisty, EPL's President and CEO, said the acquisition leverages EPL's global presence and renowned preclinical histopathology expertise with Aclairo's specialized consultation services. The combination offers clients unparalleled nonclinical and clinical drug metabolism and pharmacokinetics (DMPK) services.
"Aclairo's team of industry and ex-FDA experts have developed a specialized consultancy in drug and device development strategy with breadth and depth in the biologic, pharmaceutical and device arenas. Their expertise includes regulatory strategy and oversight, pharmacology, toxicology, DMPK, and overall program design, placement, management and interpretation," said Dr. Hardisty.
"EPL and Aclairo share a similar market and are focused on providing a tailored solution for each client. The combination of each organization's strengths will help deliver a more comprehensive product for our clients."
Aclairo provides independent and objective nonclinical, regulatory, and clinical ADME/DMPK expert strategy and implementation to the pharmaceutical and drug device industries.
The acquisition makes Aclairo a wholly owned subsidiary of EPL.
About EPL, Inc.
Experimental Pathology Laboratories, Inc. (EPL) is a Contract Research Organization which is the world's largest independent provider of GLP-compliant toxicologic pathology services. Since 1971, EPL has provided necropsy and histology support, pathology evaluation and consultation for industry and government clients. EPL operates facilities in Research Triangle Park, NC; Seattle, WA; West Lafayette, IN; and Redwood City, CA. EPL is headquartered in Sterling, VA.
About Aclairo
Aclairo Pharmaceutical Development Group, Inc. (Aclairo) has been committed for more than a decade to delivering independent and objective nonclinical, regulatory, and clinical DMPK advice to the pharmaceutical, biologics, and device industry. Aclairo is located in Vienna, VA.
Experimental Pathology Laboratories, Inc. (EPL)
www.epl-inc.com
Aclairo Pharmaceutical Development Group, Inc.
www.aclairo.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/experimental-pathology-laboratories-inc-epl-acquires-aclairo-pharmaceutical-development-group-inc-300203885.html
SOURCE EPL, Inc.
